Each year more than 4,000 new cases of pancreatic cancer are diagnosed in our country, a type of tumor that, although tenth in frequency, is the fourth cause of mortality due to any cancer disease. In fact, pancreatic cancer has the lowest survival rate associated with any tumor, with only 6% of patients surviving five years after diagnosis.

Unlike other tumors, especially lung and melanoma, pancreatic cancer does not respond to new immunotherapeutic drugs. However, researchers at the University of Washington School of Medicine in St. Louis (USA) may have found the key to immunotherapy is also effective against this type of cancer. And for this, it is only necessary to combine it with drugs capable of breaking the 'capsule' of fibrous tissue that surrounds the tumor and protects it against the treatments.